Nektar Therapeutics Shares Popped: What You Need to Know

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Oh, how sweet it is! Shares of small-cap biopharmaceutical company Nektar Therapeutics (Nasdaq: NKTR  ) spiked 16% today after the company agreed to sell the royalty rights to two of its drugs.

So what: Nektar agreed to sell its royalty rights to Cimzia, its Crohn's disease and rheumatoid arthritis drug marketed by UCB Pharma, and Mircera, a treatment for anemia sold by Roche (OTC: RHHBY). RPI Finance Trust bought the rights for $124 million. Certain thresholds were built into this agreement, so if Mircera doesn't hit undisclosed worldwide sales targets, Nektar would be on the hook through 2017 for annual payments ranging from $3 million to $7 million.

Now what: Given that Nektar is a late-stage clinical trial-based company, it's going to burn through cash in its quest for the next blockbuster drug, so today's move to secure more cash is definitely a smart one. Of course, I'm not too keen on the fact that it now has, more or less, no profit-potential royalty drugs under its wings. Selling its royalties was a necessary move, but it's not one that will get me on board with the Nektar Therapeutics bulls.

Craving more input? Start by adding Nektar Therapeutics to your free and personalized watchlist so you can keep up on the latest news with the company.

Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1796784, ~/Articles/ArticleHandler.aspx, 10/23/2016 2:48:37 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 4:00 PM
NKTR $13.34 Down -0.41 -2.98%
Nektar Therapeutic… CAPS Rating: ***